Grifols, S.A. or Travere Therapeutics, Inc.: Who Leads in Yearly Revenue?

Grifols dominates Travere in revenue growth since 2014.

__timestampGrifols, S.A.Travere Therapeutics, Inc.
Wednesday, January 1, 2014335538400028203205
Thursday, January 1, 2015393456300099892000
Friday, January 1, 20164049830000133591000
Sunday, January 1, 20174318073000154937000
Monday, January 1, 20184486724000164246000
Tuesday, January 1, 20195098691000175338000
Wednesday, January 1, 20205340038000198321000
Friday, January 1, 20214933118000227490000
Saturday, January 1, 20226063967000212018000
Sunday, January 1, 20236591977000145238000
Loading chart...

Unlocking the unknown

Grifols vs. Travere: A Revenue Showdown

In the competitive landscape of the pharmaceutical industry, Grifols, S.A. and Travere Therapeutics, Inc. have been vying for dominance in yearly revenue. Since 2014, Grifols has consistently outperformed Travere, showcasing a robust growth trajectory. By 2023, Grifols' revenue surged by approximately 97% from its 2014 figures, reaching a peak of over $6.6 billion. In contrast, Travere's revenue, while growing, remains modest, peaking at around $227 million in 2021 before a slight decline. This stark contrast highlights Grifols' strategic market positioning and operational efficiency. The data underscores Grifols' dominance, with its revenue being nearly 30 times that of Travere's in 2023. As the industry evolves, these figures provide a compelling narrative of growth, strategy, and market leadership.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025